Э.Баярмаа
Loading...
Товч нэр
Э.Баярмаа
Бүтэн нэр
Энхбат Баярмаа
Латин нэр
Enkhbat Bayarmaa
Албан тушаал
Тэнхимийн эрхлэгч
Эрдмийн цол
Профессор
Боловсролын зэрэг
Доктор (Ph.D)
ORCID
Scopus Author ID
5 results
Now showing 1 - 5 of 5
- Some of the metrics are blocked by yourconsent settings
Item type:Publication, - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Impact of IDH1 Mutation on Long-Term Survival in Patients with Diffuse Glioma(Mongolian National University of Medical Sciences, 2019-03-31) ;Enkhee Ochirjav; ;Gheeyoung ChoeObjectives: Diffuse brain gliomas are common primary brain tumor associated with a poor prognosis. In this study, we aimed to determine the impact of IDH1 mutation status on long term survival. Methods: Patients who underwent surgery for diffuse brain glioma were selected. Based on IDH1 mutation status, patients were separated into IDH1 mutant and IDH1 wildtype groups. Results: A total of 124 patients with diffuse brain tumor were included (mean age 39±17, 48.4% male). The frequency of IDH1 mutant and IDH1 wildtype were 56.5% (n=70) and 43.5% (n=54), respectively. During follow-up, 76 patients (61.3%) died and the median follow-up was 8 months (IQR 4; 16). Patients with IDH1 mutant more likely younger (36±16 vs. 43±17, p<.05) and had low grade (grade II) tumor (64.3% vs. 20.4%, p<.001). After adjustment of possible predictors, such age, gender, tumor location and surgical type, IDH1 mutant was an independent predictor of all-cause mortality (HR=0.43, 95% CI 0.26- 0.71, p<.001). Kaplan-Meier estimation showed IDH1 mutant is associated with longer survival compared with IDH1 wildtype in low grade tumor (log rank p<.001). Conclusion: Mutated IDH1 is an independent predictor of all-cause mortality in patients with diffuse brain glioma and resulted in longer survival compared with IDH1 wildtype. - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Prognostic Value of Immunohistochemical Biomarkers in Patients with Astrocytic Brain Tumor(Mongolian National University of Medical Sciences, 2018-09-25) ;Enkhee Ochirjav ;Bolortuya Dorj; Objectives: Astrocytoma is a common primary malignant brain tumor and it is typically associated with poor outcome. In this study, we aimed to determine role of various immunohistochemical (IHC) biomarkers and their relationship with patient prognosis. Methods: Patients who underwent surgery for astrocytic brain tumor were selected. Tissue specimens were collected from surgically removed tumors and stained by various IHC stains. All-cause mortality was chosen for study endpoint. Results: A total of 133 patients with who underwent surgery for astrocytic brain tumor were included (mean age 38±19 and 49.6% male). During follow-up, 84 patients (63%) died and the median time of death was 8 months (IQR 4; 16) after hospital discharge. Patients who died had higher tumor grade (60.7% vs. 34.7%, p<0.01). After adjustment of possible predictors, surgical type (HR=0.51, 95% CI 0.31-0.82, p<0.01), expression level of Ki67 (HR=1.02, 95% CI 1.00-1.04, p<0.05) and p53 (HR=1.01, 95% CI 1.00-1.02, p<0.05) were independently associated with long term mortality. Kaplan-Meier estimation showed overexpression of WT1 (42% vs. 52%, p<0.05) and Ki67 (27% vs. 58%, p<0.001) are associated with poor survival. Conclusion: IHC biomarkers are independently associated with long term prognosis in patients with astrocytic brain tumor. Overexpression of WT1 and Ki67 marker are associated with poor survival. - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Comparison of Clinical Features of Hepatitis B and C Virus-Related Hepatocellular Carcinoma(Mongolian National University of Medical Sciences, 2022-09-30); ;Erdenebileg Taivanbaatar; ; Objective: To compare the clinical characteristics of hepatitis B virus-related hepatocellular carcinoma (HBV group) and C virus-related hepatocellular carcinoma (HCV group). Methods: By a single century, we analyzed the clinical characteristics of 23 patients with hepatitis B virus-related hepatocellular carcinoma (HBV group) and 34 with hepatitis C virus-related hepatocellular carcinoma (HCV group). Results: The patients in the HBV group (mean age 61.1 year) were about 6 years younger than those in the HCV group (mean age 67.1 year). Liver function, as measured by indocyanine green retention at 15 min, was better in the HBV group (17.5 %) than in the HCV group (25.4 %). A higher proportion of the HBV group (55 %) than the HCV group (44 %) had clinical stage I. T-factor differed significantly between the groups: 53 % of the HBV group were T3 - 4 compared with 41 % of the HCV group. Furthermore, a higher proportion of the HBV group was graded 2 - 3 for tumor thrombus in the portal vein (20.3 %) and had poorly differentiated hepatocellular carcinoma (7 %) compared with the HCV group (7.1 % and 5 % respectively). Univariate analysis identified poor prognostic factors for hepatocellular carcinoma as HBV, age < or = 50 year, clinical stage II-III, a high AFP level, higher number of tumors, larger tumor size, tumor thrombus in the portal vein 2 - 3 and in the hepatic vein 2 - 3. On multivariate analysis, poor prognostic factors were a high AFP level, a higher number of tumors, and tumor thrombus in the portal vein 2 - 3 and in the hepatic vein 2 - 3, but not HBV, age, clinical stage, or tumor size. In the multiple logistic regression models on the hepatitis infection, the OR for ASAT was 2.01 (95 % CI 1.41 - 6.91), statistically significant (p < 0.05). Conclusion: These results suggest that HBV itself is not a stronger prognostic factor than HCV. - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Influence of tumor mutational burden and immune infiltration on cervical squamous cell carcinoma prognosis(2026-08-26); ; ;Shutao Tan ;Zhenyong YangYunfeng DaiIntroduction: Cervical squamous cell carcinoma (CESC) remains a significant global health challenge for women, necessitating the discovery of precise molecular biomarkers to optimize personalized treatment and immunotherapy strategies. Objective: Leveraging bioinformatics data from The Cancer Genome Atlas (TCGA) and the independent CGCI–HTMCP–CC cohort for external validation, this study rigorously evaluated the prognostic role of tumor mutational burden (TMB) in CESC. Methods: Our methodology utilized standardized transcripts per million (TPM) normalization and the maximally selected rank statistics (maxstat) algorithm to establish biologically optimal TMB thresholds, moving beyond traditional median-based stratification. Results: While somatic mutation analysis identified high frequencies in TTN (29%) and PIK3CA (27%), high TMB levels did not directly correlate with patient overall survival (p = 0.720). However, a marginal non-significant trend was observed between elevated TMB and advanced tumor T-staging (p = 0.057). Differential expression and Cox regression analyses highlighted PTGS2 as a distinctive TMB-related risk gene. Based on this, a TMB-related risk score (TMBRS) was constructed, demonstrating moderate yet consistent predictive utility (area under the curve = 0.696) across both primary and independent validation cohorts. Detailed immune profiling via Cell-type Identification by Estimating Relative Subsets of RNA Transcripts and Tumor Immune Estimation Resource revealed that high TMB and lower risk scores are specifically associated with increased infiltration of CD8+ T cells and M1 macrophages, suggesting enhanced local immune recognition. Conclusion: Although the clinical utility of the TMBRS is currently moderate, this research provides a critical proof of concept for the interplay among PTGS2, mutational load, and the tumor microenvironment, offering valuable mechanistic insights for future large-scale prospective clinical trials.
